Skip to main content
. 2021 Oct 8;12:719290. doi: 10.3389/fphar.2021.719290

FIGURE 1.

FIGURE 1

The effect of rAAV6-BMP7 gene therapy on diabetes-induced systemic and morphological changes. (A) Overview of experimental protocol, (B) body weight, (C) blood glucose, (D) glycated haemoglobin (HbA1c), (E) intraperitoneal glucose tolerance test (IPGTT; time course and AUC), (F) plasma insulin, (G) LV weight, (H) RV weight, (I) atria weight. (J) Schematic representation of the AAV vector used to achieve cardiac-selective overexpression of BMP7, containing the CMV promotor, the BMP7 gene and inverted terminal repeats (ITRs). (K) Cardiac mRNA expression of BMP7 in rAAV6-Null and rAAV6-BMP7 groups (data pooled for Control and Diabetes) and (L) in four treatment groups. Data are presented as mean ± SEM. n = 7–25 per group (see individual data points). *p < 0.05, **p < 0.01, ***p < 0.001. (B–D, F–I, L) Two-way ANOVA followed by Tukey’s post hoc test, (E) repeated measures two-way ANOVA followed by Tukey’s post hoc test, or (K) unpaired t-test. AAV, adeno-associated virus; AUC, area-under-the-curve; BMP7, bone morphogenetic protein 7; CIT, sodium citrate; CMV, cytomegalovirus virus; LV, left ventricle; RV, right ventricle.